Abstract 6108
Background
Colorectal cancer (CRC) is one of the most common cancers worldwide, and the third most common cancer in Korea. Although the number of Korean CRC survivors is estimated over 220,000, we have insufficient survivorship care program to improve survival and quality of life (QoL) of CRC survivors.
Methods
We started to build a prospective cohort on October, 2016, and collected clinicopathological and social factors from 265 Korean CRC survivors in Cancer Prevention Center, Yonsei Cancer Center, Seoul, Republic of Korea. Health-related QoL (HRQOL) was assessed using EORTC-QLQ C30, CR29, ELD14, CIPN20, and EQ-VAS in 189 CRC survivors.
Results
Median duration of cancer survivorship was 70.7 months (range, 0.7-209.8), and 80 patients (42.3%) was long term CRC survivor (who live with cancer more than 5 years). In terms of HRQOL, median scale was 63.4 (standard deviation [SD], ±21.2) for global health, 81.7 (±15.3) for function, and 19.1 (±14.7) for symptom in all CRC survivors. Symptom scale was higher in the long-term survivors (21.8 vs. 17.1; P = 0.040), and in female patients (21.4 vs. 15.3; P = 0.006). Higher stage of disease (III or IV) was related to higher symptom scale (21.6 vs. 17.2; P = 0.042), and lower functional scale (78.2 vs. 84.3; P = 0.005). Frequently reported late effects were fatigue, insomnia, flatulence, bloated feeling, defecation problem, urinary frequency, sexual dysfunction in male, and sensory neuropathy. Insomnia (P = 0.018), sexual dysfunction in male (P = 0.003), and sensory neuropathy (P = 0.043) were significantly correlated with lower HRQOL scales. In the patients who were treated with oxaliplatin (n = 41), chemotherapy-induced neuropathy is related to worse global health (hazard ratio [HR], -3.29; 95% confidence interval [CI], -8.34- -2.0; P = 0.002).
Conclusions
Various late effects are found in CRC survivors, and late effects may worsen the HRQOL of Korean CRC survivors. We are developing personalized and integrative management programs for CRC survivors.
Clinical trial identification
Legal entity responsible for the study
Yonsei University College of Medicine, Ministry of Health & Welfare, Republic of Korea.
Funding
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1631020).
Editorial Acknowledgement
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1631020).
Disclosure
All authors have declared no conflicts of interest.